Argitalpenak (47) MARÍA ITZIAR POCHEVILLE GURUCETA argitalpenak

2024

  1. Effectiveness and Safety of Direct-acting Antivirals for Treatment of Adolescents With HCV/HIV Coinfection: Real-world Data From Europe

    Pediatric Infectious Disease Journal, Vol. 43, Núm. 5, pp. E155-E159

2023

  1. Presentación de casos de esquistosomiasis de un hospital de tercer nivel en los últimos 10 años

    Boletín de la Sociedad Vasco-Navarra de pediatría = Euskal Herriko Pediatria Elkartearen aldizkaria, Núm. 124, pp. 76-76

2022

  1. Children living with HIV in Europe: do migrants have worse treatment outcomes?

    HIV Medicine, Vol. 23, Núm. 2, pp. 186-196

2021

  1. Malignancies among children and young people with HIV in Western and Eastern Europe and Thailand the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) study group

    AIDS, Vol. 35, Núm. 12, pp. 1973-1985

2020

  1. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Sociodemographic changes and trends in the rates of new perinatal HIV diagnoses and transmission in Spain from 1997 to 2015

    PLoS ONE, Vol. 14, Núm. 10

2016

  1. High Body Mass Index as a Risk Factor for Hospitalization Due to Influenza: A Case-Control Study

    Archivos de Bronconeumologia, Vol. 52, Núm. 6, pp. 299-307

2014

  1. Predictive factors of severe multilobar pneumonia and shock in patients with influenza

    Emergency Medicine Journal, Vol. 31, Núm. 4, pp. 301-307

2013

  1. Hereditary pulmonary alveolar proteinosis. Could it be triggered by Mycoplasma pneumoniae pneumonia?

    Respiratory Medicine, Vol. 107, Núm. 1, pp. 134-138

  2. Risk factors and effectiveness of preventive measures against influenza in the community

    Influenza and other Respiratory Viruses, Vol. 7, Núm. 2, pp. 177-183

2012

  1. Effectiveness of hand hygiene and provision of information in preventing influenza cases requiring hospitalization

    Preventive Medicine, Vol. 54, Núm. 6, pp. 434-439

  2. Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents

    Pediatric Infectious Disease Journal, Vol. 31, Núm. 3, pp. 273-277

  3. Prognosis of hospitalized patients with 2009 H1N1 influenza in Spain: Influence of neuraminidase inhibitors

    Journal of Antimicrobial Chemotherapy, Vol. 67, Núm. 7, pp. 1739-1745

2011

  1. Estudio de contactos en niños y adolescentes usando el QuantiFERON-TB ® gold in-tube

    Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría ( AEP ), Vol. 74, Núm. 6, pp. 363-370

  2. Estudio de contactos en niños y adolescentes usando el QuantiFERON-TB® gold in-tube

    Anales de Pediatria, Vol. 74, Núm. 6, pp. 363-370

2010

  1. Pneumococcal bacteremia in febrile infants presenting to the emergency department 8 years after the introduction of pneumococcal conjugate vaccine in the basque country of Spain

    Pediatric Infectious Disease Journal, Vol. 29, Núm. 12, pp. 1142-1144

2007

  1. Pneumococcal bacteremia among infants with fever without known source before and after introduction of pneumococcal conjugate vaccine in the Basque Country of Spain

    Pediatric Infectious Disease Journal, Vol. 26, Núm. 8, pp. 667-671

  2. Prevalencia de resistencia a fármacos antirretrovirales en España

    Anales de Pediatria, Vol. 67, Núm. 2, pp. 104-108

  3. Reduction in pediatric invasive pneumococcal disease in the Basque Country and Navarre, Spain, after introduction of the heptavalent pneumococcal conjugate vaccine

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 26, Núm. 5, pp. 303-310

2005

  1. Abnormalities in plasma fatty acid composition in human immunodeficiency virus-infected children treated with protease inhibitors

    Acta Paediatrica, International Journal of Paediatrics, Vol. 94, Núm. 6, pp. 672-677